This proposal describes biochemical studies designed to delineate specific intracellular signaling pathways involved in the regulation of cell proliferation via TGF-a /EGF-receptor binding interactions. These pathways include TGF-a-induced EGF-R phosphorylation, the association of receptor binding proteins including phospholipase C (PLC-gamma), 3'- phosphotidyl inositol protein kinase (PI 3K ) and src-family tyrosine kinase with non-catalytic regions of EGF-R. Additionally the applicant proposes that c-Ha-ras activation may be required for the mitogenic response of breast cancer cells to TGF-a or EGF and this will be evaluated. The objectives of this proposal are 1) to define differences in ligand-dependent cell proliferation induced by EGF-R phosphorylation in normal and malignant breast cells, 2) to inactivate EGF-R by introducing mutations in the tyrosine kinase binding domain and to study biochemical events occurring before and after binding of TGF-a or EGF to normal and mutant EGF-R expressing cells and 3) to elucidate the role of c-Ha-ras activation and signaling molecules such as ras GAP (GTP ase- activating protein) in TGF-a/EGF-mediated signal transduction in normal and mutant ras transfected cells. The long range goal of the proposed studies is to identify molecular events underlying tumor progression which may be potential targets for the development of rational therapeutic agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA064248-05
Application #
2895144
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Freeman, Colette S
Project Start
1995-04-14
Project End
2001-03-31
Budget Start
1999-04-01
Budget End
2001-03-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Wayne State University
Department
Pathology
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Atanaskova, Natasha; Keshamouni, Venkateshwar G; Krueger, Joseph S et al. (2002) MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene 21:4000-8
Reddy, K B; McGowen, R; Schuger, L et al. (2001) Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model. Oncogene 20:6538-43
Krueger, J S; Keshamouni, V G; Atanaskova, N et al. (2001) Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 20:4209-18
Reddy, K B; Keshamouni, V G; Chen, Y Q (1999) The level of tyrosine kinase activity regulates the expression of p21/WAF1 in cancer cells. Int J Oncol 15:301-6
Reddy, K B; Krueger, J S; Kondapaka, S B et al. (1999) Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 82:268-73
Visscher, D W; Sarkar, F H; Kasunic, T C et al. (1997) Clinicopathologic analysis of amphiregulin and heregulin immunostaining in breast neoplasia. Breast Cancer Res Treat 45:75-80
Kondapaka, B S; Reddy, K B (1996) Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Mol Cell Endocrinol 117:53-8